Research and Markets (http://www.researchandmarkets.com/research/v3cl8s/interfering_with) has announced the addition of the "Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2015" report to their offering.
Cytokines are soluble extracellular proteins or glycoproteins that are crucial intercellular regulators and mobilizers of cells engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis.
There are today 396 companies plus partners developing 572 cytokine-cytokine receptor interaction interference drugs in 1,833 developmental projects in cancer. In addition, there are 10 suspended drugs, and the accumulated number of ceased drugs over the last years amounts to another 290 drugs. Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them.
Identified drugs are linked to 277 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date, 261 out of the 265 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 44 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 106
- Pre-registration - 6
- Phase III - 72
- Phase II - 162
- Phase I - 205
- Preclinical - 238
- No Data - 13
- Suspended - 10
- Ceased - 290
For more information visit http://www.researchandmarkets.com/research/v3cl8s/interfering_with.
